Pharmaceutical Innovation: Law & the Public's Health

IMS Health Lowers 2009 Global Pharmaceutical Market Forecast to 2.5 – 3.5 Percent Growth, Press Release, April 22, 2009, available at <http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=1e61fa8adbec0210VgnVCM100000ed152ca2RCRD&vgnextchannel=b5e57900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default> (last visited May 6, 2009).

See generally Outterson K. , “Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug Markets,” Yale Journal of Health Policy, Law & Ethics 5, no. 1 (2005): 193–291.

Hunt P. , “Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines,” draft for consultation, September 19, 2007.

Bessen J. Meurer M. J. , Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk (Princeton: Princeton University Press, 2008).

PhRMA, Pharmaceutical Industry Profile (2009).

Kesselheim A. S. Avorn J. , “Using Patent Data to Assess the Value of Pharmaceutical Innovation,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 176–183.

Flynn S. Hollis A. Palmedo M. , 'An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 184–208.

Bird R. C. , “Developing Nations and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment Side Effects,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 209–221.

Lybecker K. M. Fowler E. , “Compulsory Licensing in Canada and Thailand: Comparing Regimes to Ensure Legitimate Use of the WTO Rules,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 222–239.

Sonderholm J. , “Wild-Card Patent Extensions as a Means to Incentivize Research and Development of Antibiotics,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 240–246.

Reichman J. H. , “Comment: A Trilogy of Views about Compulsory Licensing of Patented Pharmaceutical Inventions,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 247–263.

Kapczynski A. , “Commentary: Innovation Policy for a New Era,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 264–668.

Leonard E. W. , “Right to Experimental Treatment: FDA New Drug Approval, Constitutional Rights, and the Public's Health,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 269–279.

Noah B. A. , “Just a Spoonful of Sugar: Drug Safety for Pediatric Populations,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 280–291.

Crager S. E. Price M. , “Prizes and Parasites: Incentive Models for Addressing Chagas Disease,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 292–304.

Patsner B. , “Riegel v. Medtronic, Inc.: Revisiting Pre-emption for Medical Devices,” Journal of Law, Medicine & Ethics 37, no. 2 (2009): 305–317.